Shandong Anhong Pharmaceutical Co., Ltd. (formerly Qilu Antai (Linyi) Pharmaceutical Co., Ltd.) was incorporated in 2009 with a registered capital of 30 million yuan. It is a subsidiary of Shandong Qilu Pharmaceutical Group Co., Ltd. and is located at No. 29 Huayuan street, Linyi County, De Zhou City, Shandong Province. It covers a total area of 520 Mu and has more than 1600 employees. The fourth Design Institute of nuclear industry and other professional design institutes are responsible for the overall planning and detailed design of the company. The company is planned and constructed in accordance with the national drug production quality management code (GMP), the relevant specifications and standards of FDA and EU eugmp. The company was awarded the titles of national high-tech enterprise and the first batch of gazelle demonstration enterprises in Shandong Province. In 2017 and 2018, the company was awarded the top 100 enterprises with comprehensive strength of industrial enterprises in China's chemical pharmaceutical industry and the excellent enterprise brand of API export in China's chemical pharmaceutical industry. The company has established Shandong enterprise technology center, Shandong small molecule drug Engineering Technology Research Center Shandong "one enterprise, one technology" R & D center, Dezhou demonstration engineering technology research center, Dezhou Engineering Laboratory, Dezhou Key Laboratory Science and technology platform. In recent years, the company has further optimized the product structure. At present, the company has formed four series of chemical API production bases of cephalosporins, penem, anticancer and general drugs. Many product technical levels are at the international advanced level, and have passed the official certification at home and abroad such as China GMP, US FDA, Japan PMDA, Germany GMP and Korea KFDA. With good competitive advantages and strong sales force, the company's products are continuously recognized in domestic and foreign markets. It has established friendly cooperative relations with large domestic preparation manufacturers and distributors and international customers such as the United States, Japan, South Korea, Britain, Germany and Australia. Among them, the market share of Cefminox Sodium, the leading product, ranks first in the world, Meropenem's export sales volume ranks first in China, and the market share of gefitinib, sulfapride, exemestane, probucol and warfarin sodium ranks first in China, which has brought good economic benefits to the company and cooperative units. The company continues to innovate and develop and pays attention to the improvement of scientific research level. So far, more than 50 new products have been developed, and 25 projects have been listed in the national and provincial science and technology project plans; It has obtained 27 authorized national invention patents, 1 utility model patent and 1 software copyright; Won 16 national, provincial and municipal science and technology awards; 8 national standards were formulated. Gefitinib, a new anti-tumor targeted drug, has become the first "pilot variety of listing permit holder system" and "first imitation variety" in China, breaking the monopoly pattern of foreign original research in the Chinese market, and becoming the first batch of drugs that have passed the consistency evaluation of national generic drugs. Many projects have realized the successful transformation of technical achievements and achieved considerable economic and social benefits.